Skip to main content

FORMA FT4202-Hem-301 PRAISE PTV. An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE).

Clinical Trial Grant
Duke Scholars

Administered By

Medicine, Hematology

Awarded By

FORMA Therapeutics, Inc.

Start Date

April 6, 2021

End Date

March 30, 2024
 

Administered By

Medicine, Hematology

Awarded By

FORMA Therapeutics, Inc.

Start Date

April 6, 2021

End Date

March 30, 2024